Close Navigation
About Arix
Strategy
Overview
Investment Case
News
Results
Documents
Events
Calendar
Analysts
Stock info
Contact
About
Strategy
Team
Portfolio
Insights
Media
Contact
Investors
About
Strategy
Team
Portfolio
Insights
Media
Contact
Investors
Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)
25th January 2022
Useful Tools
Download, print or share this article
Print Article
Email Article
Save Article
Share Article
Twitter
LinkedIn
Facebook